Progressive Multifocal Leukoencephalopathy (PML) Treatment Market By Treatment Approach (Immune Restoration, Antiviral Therapies, Checkpoint Inhibitors, Virus-Specific T-Cell Therapies, Supportive Care); By Underlying Condition (HIV/AIDS, Multiple Sclerosis and Drug-Associated PML, Hematological Malignancies, Transplantation, Immune Disorders); By Care Setting (Academic Medical Centers, Specialty Hospitals, Cancer and Transplant Centers, Neurology Clinics, Rehabilitation Facilities); By Region (North America, Europe, Asia-Pacific, LAMEA), Segment Revenue Estimation, Forecast, 2026–2032

Progressive Multifocal Leukoencephalopathy Treatment Market: Brincidofovir, T-Cell Therapy, and Biomarker-Guided Immunotherapy Reshape an Untreated Rare Disease

The Global Progressive Multifocal Leukoencephalopathy (PML) Treatment Market is projected to grow from USD 1.34 billion in 2025 to USD 2.87 billion by 2032, expanding at a CAGR of 11.49%, according to Strategic Market Research.

 

The Progressive Multifocal Leukoencephalopathy Treatment Market remains an unusual rare-disease segment because no antiviral therapy has been approved specifically for PML. Current care focuses on restoring immune function so the body can control the JC virus. Spending is therefore distributed across antiretroviral therapy, withdrawal of immunosuppressive medicines, plasma exchange in selected cases, hospital care, neurological monitoring, diagnostic testing, rehabilitation, and experimental immunotherapies.

 

Market measurement is complicated because most treatments and services used for PML also serve much larger indications. Total sales of antiretroviral medicines, pembrolizumab, nivolumab, corticosteroids, MRI services, or hospital procedures cannot be treated as PML revenue. A credible market estimate must isolate expenditure linked to diagnosed cases, treatment episodes, specialist care, rehabilitation, and prospective PML-specific therapies.

 

Commercial development became more defined in 2026. The first patient entered an NIH-led study of intravenous brincidofovir, one of the clearest attempts to suppress JC-virus replication directly. Europe is also advancing controlled studies of virus-specific T-cell therapy and pembrolizumab. These programs are gradually shifting the market from emergency immune restoration toward antiviral, cellular, and biomarker-guided treatment strategies.

 

PML by the Numbers: Mortality, Survival, and the Scale of Unmet Need

 A French nationwide study covering 2010 to 2017 estimated PML incidence at approximately 0.11 cases per 100,000 person-years. In that cohort, 43.7% of cases were associated with HIV, while hematological malignancies accounted for 21.9% and chronic inflammatory diseases for 20.2%. This distribution shows that treatment demand now extends beyond HIV care into oncology, transplantation, rheumatology, and multiple sclerosis networks.

Overall one-year mortality in the French population was 38.2%, and the median time from diagnosis to death among patients who died was only 63 days. A Korean study reported one-year mortality of 60.0% in non-HIV PML, compared with 25.9% in HIV-associated PML. Median survival was 184 days in the non-HIV group and 1,564 days among patients with HIV, reflecting the greater difficulty of reversing immunosuppression linked to cancer, transplantation, or other underlying conditions.

In a retrospective study of 118 people with HIV-associated PML treated with antiretroviral therapy, 63.6% survived. However, approximately 42% of survivors had moderate or severe disability, sustaining demand for rehabilitation and long-term neurological care.

Emerging immune therapies have produced encouraging but still preliminary evidence. A 2024 case series involving donor-derived virus-specific T cells reported a response in 22 of 28 patients, or 79%, with 12-month survival of 69%. A 2026 international study of 111 patients treated with checkpoint inhibitors found an 86% response rate among patients with detectable virus-specific T cells, compared with 23% among those without them. These findings support biomarker-selected development rather than broad off-label use.

 

Immune Restoration Remains the Foundation of PML Treatment

Current treatment activity is determined mainly by the condition that weakened the patient’s immune system. This creates separate pathways for HIV-associated PML, medication-induced PML, hematological malignancies, transplantation, and primary immune disorders.

For untreated HIV, immediate initiation of effective combination antiretroviral therapy remains the principal intervention. Patients already receiving therapy are assessed for adherence, resistance, viral suppression, and CD4 count recovery. Wider access to antiretroviral treatment has substantially improved outcomes compared with the period before combination therapy.

Medication-associated PML generally requires discontinuation of the responsible immunosuppressive or immune-modifying drug. This is especially relevant to natalizumab-treated multiple sclerosis patients, although PML risk also appears across oncology, transplant, autoimmune, and monoclonal-antibody therapies.

Plasma exchange may be used to accelerate natalizumab clearance, but available evidence has not established a clear survival benefit. Rapid immune recovery can also trigger immune reconstitution inflammatory syndrome, or IRIS, which may worsen neurological injury through brain inflammation. Treatment therefore requires balancing viral control with the risk of an excessive inflammatory response.

Patients with blood cancers, transplants, or primary immune disorders have the largest unmet need. Reducing immunosuppression may improve JC virus control, but it can also disrupt cancer therapy, increase graft-rejection risk, or worsen the underlying disease. This conflict explains the poorer outcomes in non-HIV PML and strengthens demand for therapies that restore antiviral activity without requiring complete withdrawal of essential treatment.

 

PML Risk Expands Beyond the HIV Population

 PML was once associated mainly with advanced HIV infection. Antiretroviral therapy has reduced that concentration of cases, while wider use of potent immune-modifying medicines has created additional high-risk groups.

An analysis of the U.S. FDA Adverse Event Reporting System identified 7,244 PML reports involving 298 drugs between 2004 and 2024. Seventy-two products generated consistent reporting signals, particularly among immunomodulators, antineoplastic medicines, and biologics. These reports cannot establish incidence or prove causation, but they show that PML surveillance now spans a broad pharmaceutical and specialist-care network.

Neurologists, infectious-disease specialists, oncologists, hematologists, transplant teams, rheumatologists, hospital pharmacies, and cellular-therapy units increasingly participate in diagnosis and treatment decisions. Medication-associated risk also supports demand for anti-JC virus antibody testing, antibody-index measurement, MRI surveillance, and assessment of treatment duration and prior immunosuppressant exposure.

Earlier detection can improve the chance of stabilization before extensive neurological damage occurs. Japan’s national JC virus testing program evaluated 1,537 suspected cases through cerebrospinal-fluid PCR between fiscal years 2011 and 2020, with 288 positive results. Wider availability of sensitive testing supports faster referral and may expand the number of patients eligible for investigational therapy.

 

Brincidofovir Opens a Direct Antiviral Treatment Path

A major 2026 development was the enrollment of the first patient in an NIH-led study of intravenous brincidofovir. SymBio Pharmaceuticals announced the milestone on June 9, 2026, under a Cooperative Research and Development Agreement with the National Institute of Neurological Disorders and Stroke. The study is being conducted at the NIH Clinical Center in Maryland.

The pilot programme is evaluating safety, tolerability, JC virus activity, and preliminary effects on disease progression. Eighteen adults with PML arising from different underlying conditions are expected to complete the study. Unlike current strategies that depend mainly on immune recovery, brincidofovir is intended to act directly against viral replication.

The small study cannot yet support efficacy conclusions, and outcomes will be influenced by immune status, underlying disease, neurological damage, and concurrent treatment. Its commercial relevance lies in the possibility of a therapy that could be used across HIV, multiple sclerosis, cancer, and transplant-related PML.

Intravenous administration would initially position the product within academic medical centers and specialist hospitals. Adoption would depend on rapid diagnostic confirmation, access to infusion services, timing of treatment, reduction in viral activity, neurological outcomes, and survival. Limited patient volume could still support orphan-drug economics if the therapy demonstrates clinically meaningful benefit.

 

Virus-Specific T-Cell Therapy Enters Clinical Development

Adoptive cell therapy seeks to restore the JC virus-specific immune response that is missing in patients with PML. Donor-derived T cells are selected or prepared to recognize JC virus or the closely related BK virus.

The CurePML study sponsored by Hannover Medical School is evaluating allogeneic HPyV-2-specific T cells in a Phase II trial. It represents an important step because most previous evidence came from compassionate use, case reports, or uncontrolled series.

The 2024 experience with directly isolated virus-specific T cells provides the strongest clinical foundation for this approach. Twenty-two of 28 treated patients responded, and 12-month survival reached 69%. The absence of a concurrent randomized control limits interpretation, but the findings justify controlled development.

Cellevolve Bio has also developed CE-VST01-JC, an allogeneic JC virus-specific T-cell candidate that received U.S. investigational clearance and orphan-drug designation in 2022. Its ASCEND-JC Phase II study was designed for up to 60 participants, although public updates continued to indicate recruitment delays. The program illustrates the manufacturing, financing, patient-identification, and operational challenges facing ultra-rare cell therapies.

These treatments could command high value per patient because they require specialized laboratories, donor selection, release testing, transport, and administration at experienced centers. However, PML can deteriorate within weeks, leaving little time for matching and production. Off-the-shelf cell banks and faster logistics would materially improve commercial feasibility.

 

Biomarker-Guided Checkpoint Inhibitors Create a Precision Treatment Opportunity

Pembrolizumab and nivolumab have been used experimentally to restore antiviral T-cell activity in patients with PML. Results vary because some patients retain JC virus-specific immune cells that can be stimulated, while others lack sufficient residual immunity.

A 2026 international study of 111 patients treated at 39 centers provides evidence for stratifying these groups. Eighty-one received pembrolizumab, 28 received nivolumab, and two received atezolizumab. Among patients with detectable JC or BK virus-specific T cells, 18 of 21 responded. Only five of 22 patients without detectable virus-specific cells responded.

One-year survival probability was 89.3% in the T-cell-positive group, compared with 35.7% among T-cell-negative patients. Stronger baseline immunity may itself contribute to better outcomes, so the retrospective findings do not establish checkpoint inhibitors as universal PML therapy.

The commercial opportunity may therefore include companion diagnostics. ELISpot or flow-cytometry testing could identify patients more likely to benefit before checkpoint treatment is considered. France’s PENALTY Phase II study is evaluating pembrolizumab in immunocompromised non-HIV patients whose immune suppression is difficult to reverse, a population with particularly poor outcomes.

 

Repurposed Drugs Struggle to Build Strong Clinical Evidence

Cidofovir, mirtazapine, mefloquine, cytarabine, interferons, and other repurposed medicines have been tried based on laboratory findings or isolated reports. Controlled evidence has not demonstrated consistent survival or neurological benefit.

Current U.S. HIV opportunistic-infection guidelines do not recommend cytarabine, cidofovir, interferon alfa, or routine use of pembrolizumab for HIV-associated PML. Evidence for mirtazapine and mefloquine also remains insufficient. These products may continue to appear in individual cases, but they are unlikely to form a stable, guideline-supported market segment without stronger trial evidence.

 

Clinical Complexity and Small Patient Numbers Restrict Commercial Scale

PML’s low incidence is only one barrier to development. The patient population is highly heterogeneous: HIV-associated cases may improve with antiretroviral therapy, natalizumab-related cases may stabilize after drug withdrawal, and patients with cancer or transplantation may be unable to restore immunity. Combining these groups can obscure treatment effects.

Rapid progression also limits recruitment. Patients may become severely disabled before reaching a trial center, while deaths may result from PML, the underlying malignancy, transplantation complications, or other infections. Trials therefore need outcomes beyond survival, including cerebrospinal-fluid viral levels, MRI changes, neurological function, independence in daily activities, rehabilitation needs, and IRIS.

Successful products are unlikely to follow a high-volume commercial model. The market will resemble other orphan hospital categories, with centralized treatment, specialist distribution, intensive monitoring, and high evidence requirements.

 

Regional Research Hubs Shape the Emerging Competitive Landscape

North America is central to direct antiviral development through the NIH brincidofovir study. The region also has established HIV networks, multiple sclerosis centers, transplant programs, advanced imaging, and cell therapy infrastructure.

Europe holds a strong position in immune-based research through Hannover Medical School’s CurePML study and France’s PENALTY pembrolizumab trial. Established natalizumab risk-management systems also support JC virus testing and MRI surveillance.

Asia-Pacific activity is led by Japan-based SymBio Pharmaceuticals and Japan’s national JC virus testing experience. Near-term treatment activity will remain concentrated in major research hospitals because diagnosis and investigational treatment require specialist resources.

Competition is based on clinical progress rather than approved PML therapies. SymBio Pharmaceuticals leads the direct antiviral pathway through brincidofovir. Hannover Medical School and European partners are advancing controlled T-cell research. Cellevolve Bio is pursuing an off-the-shelf cellular candidate, while Merck, Bristol Myers Squibb, and Roche supply checkpoint inhibitors used experimentally outside approved PML indications.

Public agencies and academic centers retain an unusually important role. NIH/NINDS involvement, European academic sponsorship, and specialist-center networks reduce development barriers in a market too small and complex for conventional high-volume pharmaceutical investment..

 

Market Outlook: The Race Toward the First PML-Specific Therapy

The market’s next phase will depend on whether investigational therapies can improve outcomes beyond immune restoration. Brincidofovir must show that antiviral activity translates into neurological or survival benefits. T-cell therapies must demonstrate timely and reliable delivery, while checkpoint inhibitors require biomarker-based patient selection.

A successful PML-specific therapy would create a concentrated orphan-disease market built around urgent hospital treatment, limited competition, specialist distribution, and substantial value per treated patient. The strongest opportunities are likely to come from therapies that work across several underlying conditions, can be administered soon after diagnosis, and improve functional outcomes rather than laboratory or imaging measures alone.

 

Progressive Multifocal Leukoencephalopathy Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 1.34 Billion
Revenue Forecast in 2032	USD 2.87 Billion
Overall Growth Rate	CAGR of 11.49% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Treatment Approach, By Underlying Condition, By Care Setting, By Geography
By Treatment Approach	Immune Restoration, Antiviral Therapies, Checkpoint Inhibitors, Virus-Specific T-Cell Therapies, Supportive Care
By Underlying Condition	HIV/AIDS-Associated PML, Multiple Sclerosis and Drug-Associated PML, Hematological Malignancies, Transplantation-Related PML, Primary and Other Immune Disorders
By Care Setting	Academic Medical Centers, Specialty Hospitals, Cancer and Transplant Centers, Neurology Clinics, Rehabilitation Facilities
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Growing demand for therapies addressing severe unmet need in PML, expansion of JC virus diagnostic capabilities, rising PML incidence linked with immunosuppressive therapies, advancement of antiviral candidates and immune-based treatment approaches, increasing investment in rare neurological disease research
Customization Option	Available upon request